… Eligible studies modeled the impact of a cancer risk management intervention in BRCA
carriers on life expectancy (LE), cancer incidence, or quality-adjusted life years (QALYs), with or …

… have a significantly elevated lifetime risk of breast cancer (BC) and ovarian cancer (OC). An
… risk estimates for the individual to guide management decisions. Female mutation carriers …

… cancer risk and decision-making, we excluded women with a previous or current ovarian
cancer … right, and normalization of cancer risk management to participants during the decision-…

… cancer risks for BRCA1 and BRCA2 mutation carriers from meta-analyses. Since approximately
30% of BRCA1/2 mutation carriers … that reported breast cancer incidence 2 incorporates …

… Primary studies of BRCA mutation carriers who have undergone BRRM in … risk reduction
in breast cancer incidence. The risk of breast cancer after BRRM is less than 3%, and the risk …

… role that risk modifiers may contribute to the risk assessment … regarding cancer risk modifiers
in BRCA1/2 mutation carriers … inform the use of risk modifiers in cancer risk counseling, as …

… management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers
… high-risk women’s preferences about cancer risk management and reproductive options …

… cancer risk (1), genetic cancer risk assessment (GCRA) enables informed choices about
cancer … The largest study of PALB2 mutation carriers to date indicated that the cumulative risk of …

… Using a simple, more valid method of analysis, we found no evidence for first BC risk
reduction after RRSO in BRCA1/2 mutation carriers. We suggest that counselors, clinicians, and …

… important cancer risk reduction management strategy for women with BRCA1/2 mutations. …
for HRT, women with BRCA1/2 mutations should be discouraged from deferring BPO because …